IGF2BP1 inhibition was associated with a higher T cell-to-tumor cell ratio, as confirmed by flow cytometry and RNA-seq of FACS-separated tumor and immune cells (Fig. 6c and Supplementary Fig. S6c). This evidence concerns the gene IGF2BP1 and neoplasm.